

Special Issue

Advances in Immunotherapy for Genitourinary Malignancies

Message from the Guest Editor

Over the last few years, immunotherapy has become an increasingly attractive treatment modality in many solid tumors, including genitourinary malignancies. Novel immunotherapy strategies offer a promising approach to improve the overall survival and quality of life outcomes for cancer patients. The discovery of checkpoint inhibitors has significantly changed the field of cancer immunotherapy. However, more studies will be required to understand how to manipulate the immune system to improve anti-tumor activity by combining checkpoint inhibitors with other immune co-stimulatory therapies and/or conventional cancer therapies. In this Special Issue, experts in the field will review and present advances in understanding and modulating the immune microenvironment of genitourinary malignancies.

Guest Editor

Prof. Amirali Salmasi

Department of Urology, University of California, San Diego Health, San Diego, CA 92103, USA

Deadline for manuscript submissions

closed (15 August 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/61413

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)